Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares OutstandingShares Outstanding
Ratios

Tango Therapeutics (TNGX) Accumulated Depreciation & Amortization (2020 - 2025)

Tango Therapeutics has reported Accumulated Depreciation & Amortization over the past 6 years, most recently at $10.5 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $10.5 million for Q4 2025, up 26.01% from a year ago — trailing twelve months through Dec 2025 was $10.5 million (up 26.01% YoY), and the annual figure for FY2025 was $10.5 million, up 26.01%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $10.5 million at Tango Therapeutics, up from $10.1 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for TNGX hit a ceiling of $10.5 million in Q4 2025 and a floor of $2.3 million in Q3 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $5.7 million (2023), compared with a mean of $6.0 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 68.16% in 2023 and later increased 26.01% in 2025.
  • Tango Therapeutics' Accumulated Depreciation & Amortization stood at $2.5 million in 2021, then surged by 45.55% to $3.7 million in 2022, then skyrocketed by 62.7% to $6.0 million in 2023, then skyrocketed by 39.64% to $8.4 million in 2024, then increased by 26.01% to $10.5 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $10.5 million (Q4 2025), $10.1 million (Q3 2025), and $9.6 million (Q2 2025) per Business Quant data.